

2008 BBVA Foundation Frontiers of Knowledge Awards

AWARD DECISION

BIOMEDICINE CATEGORY

Madrid, January 26, 2009.

The jury of the **2008 BBVA Foundation Frontiers of Knowledge Awards** in the **Biomedicine** category, formed by:

CHAIR OF THE JURY

Prof. Torsten WIESEL	The Nobel Prize in Physiology or Medicine Human Frontier Science Program France
-----------------------------	---

MEMBERS

Prof. Dario ALESSI	MRC Protein Phosphorylation Unit University of Dundee United Kingdom
Prof. José BASELGA	Vall d'Hebron Institute of Oncology (V.H.I.O.) Vall d'Hebron University Hospital Spain
Dr. Robin LOVELL-BADGE	Stem Cell Biology and Developmental Genetics National Institute for Medical Research United Kingdom
Prof. Angelika SCHNIEKE	Lehrstuhl fuer Biotechnologie der Nutztiere Technische Universität München Germany
Prof. Bruce WHITELAW	Division of Developmental Biology The Roslin Institute and R(D)SVS University of Edinburgh United Kingdom

SECRETARY

Prof. Juan MODOLELL	Molecular Biology of Development Severo Ochoa Molecular Biology Center Autonomous University of Madrid-Spanish Council for Scientific Research Spain
----------------------------	--

Meeting together on January 26, 2009 in the offices of the BBVA Foundation in Madrid, Spain in order to deliberate and decide, have resolved to grant the

2008 BBVA Foundation Frontiers of Knowledge Award in the Biomedicine category

Award-winning nomination:

Dr. Joan Massagué

Reasons for award:

The BBVA Foundation Frontiers of Knowledge Award in Biomedicine corresponding to the year 2008 has been conferred upon Dr. Joan Massagué for elucidating one of the fundamental processes that control cell division, namely, the machinery that conveys the growth inhibitory signal of TGF-beta from the cell membrane to the nucleus. Many of the components of this signaling transduction pathway have been identified and functionally characterized by Dr. Massagué. The TGF-beta pathway is crucial for the development of all animals, and when disrupted, contributes to diseases such as cancer. Massagué and colleagues have also developed novel approaches to identify genes involved in organ-specific metastasis. These studies have considerably increased the understanding of metastasis and have great potential for clinical application, given that 90 percent of cancer-related deaths are due to this invasive process.

And in witness whereof sign the present document in the place and on the date first above written.

CHAIR OF THE JURY



Prof. Torsten WIESEL

MEMBERS



Prof. Dario ALESSI



Prof. José BASELGA



Dr. Robin LOVELL-BADGE



Prof. Angelika SCHNIEKE



Prof. Bruce WHITELAW

SECRETARY



Prof. Juan MODOLELL